Neoplasms

Respiratory Tract (Lung and Bronchial) Diseases

All Conditions

Carcinoma, Non-Small-Cell Lung

Lung Neoplasms

Carcinoma

Respiratory Tract Neoplasms

Thoracic Neoplasms

Lung Diseases

Respiratory Tract Diseases

Carcinoma, Bronchogenic

Bronchial Neoplasms

Antineoplastic Agents

All Drugs and Chemicals

Paclitaxel

Carboplatin

Etoposide

Gemcitabine

Vinorelbine

Pembrolizumab

Docetaxel

Albumin-Bound Paclitaxel

Cisplatin

Immunomodulating Agents

Etoposide phosphate

Nedaplatin

The patient will receive carbon ion radiotherapy with 70Gy per 20 fractions. Patients with genetic mutations (including but not limited to EGFR, ALK, etc.) should receive targeted therapy as their systemic therapy. For patients who are not suitable for targeted therapy, we recommend single regimen chemotherapy in sequence with radiotherapy. The drugs include etoposide, platinum (carboplatin, cisplatin, nedaplatin or loplatin), vinorelbine, paclitaxel (including liposome paclitaxel and albumin paclitaxel), docetaxel, pemetrexel, gemcitabine, etc. If there is no contraindication to PD-1/PD-L1 immunotherapy, it can be combined with immunotherapy, such as Pembrolizumab. For patients who cannot tolerate chemotherapy, PD-1/PD-L1 immunotherapy is recommended. The progression-free survival rate, toxicity, local control rate, cause-specific survival rate and overall survival rate were observed with regular follow-up after treatment.

carbon ion radiotherapy

targeted therapy

single regimen chemotherapy in sequence with radiotherapy

Jing Li

Kun Liu

Jian Chen, MD

Jingfang Mao, PHD

Kai-liang Wu, PHD

To observe the effect and toxicity of carbon ion radiotherapy on local advanced non-small cell lung cancer over 75 years old patients. Systemic therapy could be targeted therapy, chemotherapy or immunotherapy.

Carbon Ion Radiotherapy for Locally Advanced Lung Cancer in Elderly Patients

A Prospective Phase II Clinical Study of Carbon Ion Radiotherapy for Locally Advanced Non-small Cell Lung Cancer in the Older Adult

Disease progression-free survival rate was defined from the start of carbon ion radiotherapy till the date of disease progression at any site or death, or the last follow up.

Treatment-induced toxicities were scored using the Common Terminology Criteria for Adverse Events (CTCAE) version 5.0, for events observed after the first dose of irradiation. Toxicities occurred 90 or more days after the completion of CIRT were defined as late toxicities.

Local control rate was defined from the start of carbon ion radiotherapy till the date of local failure or the last follow-up

Cause-specific survival rate was defined from the start of carbon ion radiotherapy till the date of death caused by non-small cell lung cancer treated in this study or the last follow-up

Overall survival rate was defined from the start of carbon ion radiotherapy till the date of death or the last follow-up.

Jian Chen

Clinical Professor

Study title	NCT ID	Conditions	Interventions	Eligibility	Organization
Carbon Ion Radiotherapy for Locally Advanced Lung Cancer in Elderly Patients	NCT06311981	Non-small Cell ... Older People Carbon Ion Radi... Radiotherapy Si...	carbon ion radi... targeted therap... single regimen ...	75 Years -	Shanghai Proton and Heavy Ion Center
Carbon Ion Radiotherapy for Locally Advanced Lung Cancer in Elderly Patients	NCT06311981	Non-small Cell ... Older People Carbon Ion Radi... Radiotherapy Si...	carbon ion radi... targeted therap... single regimen ...	75 Years -	Shanghai Proton and Heavy Ion Center
Carbon Ion Radiotherapy for Locally Advanced Lung Cancer in Elderly Patients	NCT06311981	Non-small Cell ... Older People Carbon Ion Radi... Radiotherapy Si...	carbon ion radi... targeted therap... single regimen ...	75 Years -	Shanghai Proton and Heavy Ion Center

Spots Global Cancer Trial Database for single regimen chemotherapy in sequence with radiotherapy